21 March 2022 - This is the first time we can recall that the DoH has published a revised agenda for a PBAC meeting that has already been convened.

The revised agenda notes it is version 6; we make it version 7.

Version 6 (7) has five amendments:

• Venetoclax (Venclexta) - withdrawn
• Nicotine replacement therapy – withdrawn
• Pembrolizumab (Keytruda) for squamous cell carcinoma of the head and neck - new item
• Influenza vaccine (quadrivalent, adjuvanted) (Flucelvax Quad) - withdrawn
• Bimekizumab (Bimzelx) for chronic plaque psoriasis – revised target patient population

The first three amendments were noted in the previous version.

The revised agenda states that the purpose of the submission for bimekizumab has changed. That is not accurate; the purpose remains the same; to list a new medicine (bimekizumab) on the PBS. What has changed is the target patient population; it was  adults with moderate to severe plaque psoriasis; it has changed to adults with severe plaque psoriasis.